Search Results - "Vassilakopoulos, T P"

Response to ‘PET after response to R-CHOP in primary mediastinal large B-cell lymphoma’ by Vassilakopoulos, TP, Papageorgiou, S, Pangalis, GA, Chatziioannou, S, Angelopoulou, MK, Panayiotidis, P, Konstantopoulos, K, Rondogianni, P

Get full text

Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib by Georgiou, G, Efthymiou, A, Vardounioti, I, Boutsikas, G, Angelopoulou, M K, Vassilakopoulos, T P, Kyrtsonis, M-C, Plata, E, Tofas, P, Bitsani, A, Bartzi, V, Pessach, I, Dimou, M, Panayiotidis, P

Get full text

Rituximab monotherapy is highly effective in splenic marginal zone lymphoma by Kalpadakis, C, Pangalis, GA, Dimopoulou, MN, Vassilakopoulos, TP, Kyrtsonis, M-C, Korkolopoulou, P, Kontopidou, FN, Siakantaris, MP, Dimitriadou, EM, Kokoris, SI, Tsaftaridis, P, Plata, E, Angelopoulou, MK

“…Splenectomy has traditionally been considered as a standard first line treatment for splenic marginal zone lymphoma (SMZL) conferring a survival advantage over…”
Get full text

Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications by KORKOLOPOULOU, P, THYMARA, I, TSENGA, A, ANDROULAKI, A, DOUSSIS-ANAGNOSTOPOULOU, I. A, PATSOURIS, E, PANGALIS, G. A, KAVANTZAS, N, VASSILAKOPOULOS, T. P, ANGELOPOULOU, M. K, KOKORIS, S. I, DIMITRIADOU, E. M, SIAKANTARIS, M. P, ANARGYROU, K, PANAYIOTIDIS, P

“…The significance of angiogenesis in Hodgkin's lymphoma (HL) is not well defined. The aim of this study was to evaluate various morphometric characteristics of…”
Get full text

PUVA plus interferon α2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series by Nikolaou, V, Siakantaris, MP, Vassilakopoulos, TP, Papadavid, E, Stratigos, A, Economidi, A, Marinos, L, Papadaki, T, Antoniou, C

“…Background  The combination of PUVA with variable doses of systemically administered interferon α2b (IFN‐α2b) reduces the number of PUVA treatments and the…”
Get full text

Primary Effusion Lymphoma in Two HIV-Negative Patients Successfully Treated with Pleurodesis as First-line Therapy by IAKOUMIS, X, PANGALIS, G. A, SACHANAS, S, ANDREOPOULOS, A, KYRTSONIS, M.-C, VASSILAKOPOULOS, T. P, KONTOPIDOU, F. N, KALPADAKIS, C, KORKOLOPOULOU, P, LEVIDOU, G, ANDROULAKI, A, SIAKANTARIS, M. P

“…Primary effusion lymphoma (PEL) is a rare non-Hodgkin's lymphoma (NHL) mostly occurring in HIV-positive patients. It is characterized by the development of…”
Get full text

Topoisomerase IIα as a prognostic factor in mantle cell lymphoma by KORKOLOPOULO, P, VASSILAKOPOULOS, T. P

Get full text

High serum levels of B‐lymphocyte stimulator are associated with clinical–pathological features and outcome in classical Hodgkin lymphoma by Tecchio, C., Nadali, G., Scapini, P., Bonetto, C., Visco, C., Tamassia, N., Vassilakopoulos, T. P., Pangalis, G. A., Calzetti, F., Nardelli, B., Roschke, V., Gottardi, M., Zampieri, F., Gherlinzoni, F., Facchetti, F., Pizzolo, G., Cassatella, M. A.

“…Summary B‐lymphocyte stimulator (BLyS) acts as survival factor for B lymphocytes. As Hodgkin and Reed‐Sternberg (HRS) cells express receptors through which…”
Get full text

Genetic polymorphisms and risk of MALT lymphoma in Greek population by Velissari, A., Vassilakopoulos, T.P, Angelopoulou, M.K, Korkolopoulou, P, Bamias, G., Daikos, G., Konstantopoulos, K., Siakantaris, M.

“…MALT lymphoma is thought to have a genetic component. Genetic studies in the greek population are rare and genetic determinants remain to be established. The…”
Get full text

EVALUATION OF GONADAL FUNCTION IN YOUNG MEN AND WOMEN DIAGNOSED WITH HODGKIN LYMPHOMA by Georgopoulou, A. N., Vassilakopoulos, T. P., Panayiotidis, P., Siakantaris, M., Keramaris, K., Georgopoulos, N. A., Kalantaridou, S., Arapaki, M., Chatzidimitriou, C., Kopsaftopoulou, A., Mamali, I., Angelopoulou, M. K.

Get full text

CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study by Munoz, J., Hoffmann, M., Westin, J., Vassilakopoulos, T. P., García‐Sancho, A. M., Rueda‐Domínguez, A., Jurczak, W., Kwiatek, M., Bouzani, M., Gkasiamis, A., Patel, A., Boucaud, F., Li, J., Nowakowski, G. S.

Get full text

PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy by Vassilakopoulos, T P, Pangalis, G A, Chatziioannou, S, Papageorgiou, S, Angelopoulou, M K, Galani, Z, Kourti, G, Prassopoulos, V, Leonidopoulou, T, Terpos, E, Dimopoulou, M N, Sachanas, S, Kalpadakis, C, Konstantinidou, P, Boutsis, D, Stefanoudaki, E, Kyriazopoulou, L, Siakantaris, M P, Kyrtsonis, M-C, Variami, E, Kotsianidis, I, Symeonidis, A, Michali, E, Katodritou, E, Kokkini, G, Tsatalas, C, Papadaki, H, Dimopoulos, M-A, Sotiropoulos, V, Pappa, V, Karmiris, T, Meletis, J, Apostolidis, J, Datseris, I, Panayiotidis, P, Konstantopoulos, K, Roussou, P, Rondogianni, P

Get full text

TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA EXPERIENCING VERY LATE RELAPSES AFTER CHEMOTHERAPY ± RADIOTHERAPY by Vassilakopoulos, T. P., Liaskas, A., Rizzuto, G., Symeonidis, A., Palma, M., Angelopoulou, M. K., Giatra, C., Spanoudakis, E., Oikonomopoulos, P., Kondopidou, F. N., Dimou, M., Musseti, A., Xagoraris, I., Siakantaris, M., Panitsas, F., Asimakopoulos, J., Arapaki, M., Chatzidimitriou, C., Belia, M., Sachanas, S., Korkolopoulou, P., Cabras, A., Variami, E., Panayotidis, P., Bakiri, M., Karmiris, T., Rassidakis, G., Corradini, P., Pangalis, G. A., Viviani, S.

Get full text

Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders by Pangalis, G A, Dimopoulou, M N, Angelopoulou, M K, Tsekouras, C, Vassilakopoulos, T P, Vaiopoulos, G, Siakantaris, M P

“…Campath-1H is a humanized monoclonal antibody targeted against the CDw52 membrane antigen of lymphocytes, which causes complement and antibody-dependent…”
Get full text

FLT3 Overexpression in Acute Promyelocytic Leukemia Patients without Detectable FLT3-ITD or Codon 835-836 Mutations: A Pilot Study by LILAKOS, K, VINIOU, N. A, XILOURI, I, GALANOPOULOS, A, AGELOUDI, M, PANAYIOTID S, P, VOULGARELIS, M, ROMBOS, J, MELETIS, J, YATAGANAS, X, PANGALIS, G. A, MAVROGIANNI, D, VASSILAKOPOULOS, T. P, DIMOPOULOU, M. N, PLATA, E, ANGELOPOULOU, M. K, VARIAMI, E, STAVROGIANNI, N, LIAPI, D

“…Background: Activating mutations of the FLT3 receptor tyrosine kinase are common in acute promyelocytic leukemia (APL) but have uncertain prognostic…”
Get full text

B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders by Pangalis, G A, Angelopoulou, M K, Vassilakopoulos, T P, Siakantaris, M P, Kittas, C

“…Among small lymphocyte cell disorders, B-chronic lymphocytic leukemia (B-CLL), small lymphocytic lymphoma (SLL), and lymphoplasmacytic lymphoma/Waldenström's…”
Get more information

PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT by Ferreri, A. J.M., Tarantino, V., Cabras, G., Ferrara, F., Zinzani, P. L., Arcaini, L., Castellino, A., Tucci, A., Cocito, F., Davies, A., Salvador Chalup, M. M.B, Cwynarski, K., Nogueira, F. L., Petrucci, L., Muzi, C., Onofrillo, D., Ferrario, A., Ramakrishnan, P., Scalzulli, P. R., Tani, M., Tisi, M. C., Papageorgiou, S. G., Calimeri, T., Angelillo, P., Foppoli, M., Dimou, M., Ponzoni, M., Iannitto, E., Vassilakopoulos, T. P.

Get full text

P1085: EVALUATION OF GONADAL FUNCTION IN YOUNG WOMEN DIAGNOSED WITH HODGKIN AND NON‐HODGKIN LYMPHOMA by Georgopoulou, A. N., Giannakou, A., Vassilakopoulos, T. P., Siakantaris, M., Georgopoulos, N. A., Kalantaridou, S., Lalou, E., Keramaris, K., Loukari, E., Arapaki, M., Konstantinou, I., Machairas, A., Kopsaftopoulou, A., Mammali, I., Vassilopoulos, I., Galopoulos, D., Angelopoulou, M. K.

Get full text

Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma by Vassilakopoulos, TP, Nadali, G, Angelopoulou, MK, Siakantaris, MP, Dimopoulou, MN, Kontopidou, FN, Rassidakis, GZ, Doussis-Anagnostopoulou, IA, Hatzioannou, M, Vaiopoulos, G, Kittas, C, Sarris, AH, Pizzolo, G, Pangalis, GA

“…Hematology Section, First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece. BACKGROUND…”
Get full text

Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites by Vassilakopoulos, T.P., Angelopoulou, M.K., Siakantaris, M.P., Kontopidou, F.N., Dimopoulou, M.N., Barbounis, A., Grigorakis, V., Karkantaris, C., Anargyrou, K., Chatziioannou, M., Rombos, J., Boussiotis, V.A., Vaiopoulos, G., Kittas, C., Pangalis, G.A.

“…: Background: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60–70% of patients. The pretreatment identification of a sizeable…”
Get full text